1. Market Research
  2. > All Companies
  3. > Multiple Myeloma (Kahler%s Disease) - Pipeline Review, H1 2015

Multiple Myeloma (Kahler%s Disease) - Pipeline Review, H1 2015

  • June 2015
  • -
  • Global Markets Direct
  • -
  • 986 pages

Multiple Myeloma (Kahler's Disease) - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Multiple Myeloma (Kahler's Disease) - Pipeline Review, H1 2015’, provides an overview of the Multiple Myeloma (Kahler's Disease)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler's Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Multiple Myeloma (Kahler's Disease) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Multiple Myeloma (Kahler's Disease)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Multiple Myeloma (Kahler's Disease) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Multiple Myeloma (Kahler's Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Multiple Myeloma (Kahler's Disease) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Multiple Myeloma (Kahler's Disease)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Multiple Myeloma (Kahler's Disease) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Multiple Myeloma (Kahler%s Disease) - Pipeline Review, H1 2015
Table of Contents
Table of Contents 2
Introduction 9
Multiple Myeloma (Kahler's Disease) Overview 10
Therapeutics Development 11
Multiple Myeloma (Kahler's Disease) - Therapeutics under Development by Companies 13
Multiple Myeloma (Kahler's Disease) - Therapeutics under Investigation by Universities/Institutes 26
Multiple Myeloma (Kahler's Disease) - Pipeline Products Glance 30
Multiple Myeloma (Kahler's Disease) - Products under Development by Companies 34
Multiple Myeloma (Kahler's Disease) - Products under Investigation by Universities/Institutes 55
Multiple Myeloma (Kahler's Disease) - Companies Involved in Therapeutics Development 58
Multiple Myeloma (Kahler's Disease) - Therapeutics Assessment 190
Drug Profiles 219
Multiple Myeloma (Kahler's Disease) - Recent Pipeline Updates 665
Multiple Myeloma (Kahler's Disease) - Dormant Projects 924
Multiple Myeloma (Kahler's Disease) - Discontinued Products 941
Multiple Myeloma (Kahler's Disease) - Product Development Milestones 946
Appendix 957

List of Tables
Number of Products under Development for Multiple Myeloma (Kahler's Disease), H1 2015 39
Number of Products under Development for Multiple Myeloma (Kahler's Disease) - Comparative Analysis, H1 2015 40
Number of Products under Development by Companies, H1 2015 42
Number of Products under Development by Companies, H1 2015 (Contd..1) 43
Number of Products under Development by Companies, H1 2015 (Contd..2) 44
Number of Products under Development by Companies, H1 2015 (Contd..3) 45
Number of Products under Development by Companies, H1 2015 (Contd..4) 46
Number of Products under Development by Companies, H1 2015 (Contd..5) 47
Number of Products under Development by Companies, H1 2015 (Contd..6) 48
Number of Products under Development by Companies, H1 2015 (Contd..7) 49
Number of Products under Development by Companies, H1 2015 (Contd..8) 50
Number of Products under Development by Companies, H1 2015 (Contd..9) 51
Number of Products under Development by Companies, H1 2015 (Contd..10) 52
Number of Products under Development by Companies, H1 2015 (Contd..11) 53
Number of Products under Investigation by Universities/Institutes, H1 2015 55
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 56
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 57
Comparative Analysis by Late Stage Development, H1 2015 58
Comparative Analysis by Clinical Stage Development, H1 2015 59
Comparative Analysis by Early Stage Development, H1 2015 60
Comparative Analysis by Unknown Stage Development, H1 2015 61
Products under Development by Companies, H1 2015 62
Products under Development by Companies, H1 2015 (Contd..1) 63
Products under Development by Companies, H1 2015 (Contd..2) 64
Products under Development by Companies, H1 2015 (Contd..3) 65
Products under Development by Companies, H1 2015 (Contd..4) 66
Products under Development by Companies, H1 2015 (Contd..5) 67
Products under Development by Companies, H1 2015 (Contd..6) 68
Products under Development by Companies, H1 2015 (Contd..7) 69
Products under Development by Companies, H1 2015 (Contd..8) 70
Products under Development by Companies, H1 2015 (Contd..9) 71
Products under Development by Companies, H1 2015 (Contd..10) 72
Products under Development by Companies, H1 2015 (Contd..11) 73
Products under Development by Companies, H1 2015 (Contd..12) 74
Products under Development by Companies, H1 2015 (Contd..13) 75
Products under Development by Companies, H1 2015 (Contd..14) 76
Products under Development by Companies, H1 2015 (Contd..15) 77
Products under Development by Companies, H1 2015 (Contd..16) 78
Products under Development by Companies, H1 2015 (Contd..17) 79
Products under Development by Companies, H1 2015 (Contd..18) 80
Products under Development by Companies, H1 2015 (Contd..19) 81
Products under Development by Companies, H1 2015 (Contd..20) 82
Products under Investigation by Universities/Institutes, H1 2015 83
Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 84
Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 85
Multiple Myeloma (Kahler's Disease) - Pipeline by 4SC AG, H1 2015 86
Multiple Myeloma (Kahler's Disease) - Pipeline by AB Science, H1 2015 87
Multiple Myeloma (Kahler's Disease) - Pipeline by AbbVie Inc., H1 2015 88
Multiple Myeloma (Kahler's Disease) - Pipeline by Ablynx NV, H1 2015 89
Multiple Myeloma (Kahler's Disease) - Pipeline by Acceleron Pharma, Inc., H1 2015 90
Multiple Myeloma (Kahler's Disease) - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2015 91
Multiple Myeloma (Kahler's Disease) - Pipeline by Actinium Pharmaceuticals, Inc., H1 2015 92
Multiple Myeloma (Kahler's Disease) - Pipeline by Adaptimmune Limited, H1 2015 93
Multiple Myeloma (Kahler's Disease) - Pipeline by Advancell, H1 2015 94
Multiple Myeloma (Kahler's Disease) - Pipeline by Affimed Therapeutics AG, H1 2015 95
Multiple Myeloma (Kahler's Disease) - Pipeline by Altor BioScience Corporation, H1 2015 96
Multiple Myeloma (Kahler's Disease) - Pipeline by Amgen Inc., H1 2015 97
Multiple Myeloma (Kahler's Disease) - Pipeline by Amorfix Life Sciences Ltd., H1 2015 98
Multiple Myeloma (Kahler's Disease) - Pipeline by Anthera Pharmaceuticals‚ Inc., H1 2015 99
Multiple Myeloma (Kahler's Disease) - Pipeline by APIM Therapeutics AS, H1 2015 100
Multiple Myeloma (Kahler's Disease) - Pipeline by APO-T B.V., H1 2015 101
Multiple Myeloma (Kahler's Disease) - Pipeline by Aptose Biosciences Inc., H1 2015 102
Multiple Myeloma (Kahler's Disease) - Pipeline by Arcarios BV, H1 2015 103
Multiple Myeloma (Kahler's Disease) - Pipeline by Arno Therapeutics, Inc., H1 2015 104
Multiple Myeloma (Kahler's Disease) - Pipeline by Array BioPharma Inc., H1 2015 105
Multiple Myeloma (Kahler's Disease) - Pipeline by Astellas Pharma Inc., H1 2015 106
Multiple Myeloma (Kahler's Disease) - Pipeline by Astex Pharmaceuticals, Inc., H1 2015 107
Multiple Myeloma (Kahler's Disease) - Pipeline by Aurigene Discovery Technologies Limited, H1 2015 108
Multiple Myeloma (Kahler's Disease) - Pipeline by AVEO Pharmaceuticals, Inc., H1 2015 109
Multiple Myeloma (Kahler's Disease) - Pipeline by AvidBiotics Corp., H1 2015 110
Multiple Myeloma (Kahler's Disease) - Pipeline by Axelar AB, H1 2015 111
Multiple Myeloma (Kahler's Disease) - Pipeline by Bayer AG, H1 2015 112
Multiple Myeloma (Kahler's Disease) - Pipeline by Biogenomics Limited, H1 2015 113
Multiple Myeloma (Kahler's Disease) - Pipeline by BioInvent International AB, H1 2015 114
Multiple Myeloma (Kahler's Disease) - Pipeline by BioNovion B.V., H1 2015 115
Multiple Myeloma (Kahler's Disease) - Pipeline by Biotest AG, H1 2015 116
Multiple Myeloma (Kahler's Disease) - Pipeline by Bluebird bio, Inc., H1 2015 117
Multiple Myeloma (Kahler's Disease) - Pipeline by Boston Biomedical, Inc., H1 2015 118
Multiple Myeloma (Kahler's Disease) - Pipeline by Bristol-Myers Squibb Company, H1 2015 119
Multiple Myeloma (Kahler's Disease) - Pipeline by Calithera Biosciences, Inc., H1 2015 120
Multiple Myeloma (Kahler's Disease) - Pipeline by Celgene Corporation, H1 2015 121
Multiple Myeloma (Kahler's Disease) - Pipeline by Cellectar Biosciences, Inc., H1 2015 122
Multiple Myeloma (Kahler's Disease) - Pipeline by Cellectis S.A., H1 2015 123
Multiple Myeloma (Kahler's Disease) - Pipeline by Cellerant Therapeutics, Inc., H1 2015 124
Multiple Myeloma (Kahler's Disease) - Pipeline by Celleron Therapeutics Limited, H1 2015 125
Multiple Myeloma (Kahler's Disease) - Pipeline by Celyad, H1 2015 126
Multiple Myeloma (Kahler's Disease) - Pipeline by ChemoCentryx, Inc., H1 2015 127
Multiple Myeloma (Kahler's Disease) - Pipeline by Compugen Ltd., H1 2015 128
Multiple Myeloma (Kahler's Disease) - Pipeline by Concert Pharmaceuticals, Inc., H1 2015 129
Multiple Myeloma (Kahler's Disease) - Pipeline by Constellation Pharmaceuticals, Inc., H1 2015 130
Multiple Myeloma (Kahler's Disease) - Pipeline by CureTech Ltd., H1 2015 131
Multiple Myeloma (Kahler's Disease) - Pipeline by Curis, Inc., H1 2015 132
Multiple Myeloma (Kahler's Disease) - Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2015 133
Multiple Myeloma (Kahler's Disease) - Pipeline by Daiichi Sankyo Company, Limited, H1 2015 134
Multiple Myeloma (Kahler's Disease) - Pipeline by DARA BioSciences, Inc., H1 2015 135
Multiple Myeloma (Kahler's Disease) - Pipeline by Dicerna Pharmaceuticals, Inc., H1 2015 136
Multiple Myeloma (Kahler's Disease) - Pipeline by Eli Lilly and Company, H1 2015 137
Multiple Myeloma (Kahler's Disease) - Pipeline by Enceladus Pharmaceuticals BV, H1 2015 138
Multiple Myeloma (Kahler's Disease) - Pipeline by Exelixis, Inc., H1 2015 139
Multiple Myeloma (Kahler's Disease) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 140
Multiple Myeloma (Kahler's Disease) - Pipeline by Fortress Biotech, Inc., H1 2015 141
Multiple Myeloma (Kahler's Disease) - Pipeline by Gamida Cell Ltd., H1 2015 142
Multiple Myeloma (Kahler's Disease) - Pipeline by Genentech, Inc., H1 2015 143
Multiple Myeloma (Kahler's Disease) - Pipeline by GlaxoSmithKline Plc, H1 2015 144
Multiple Myeloma (Kahler's Disease) - Pipeline by Gliknik, Inc., H1 2015 145
Multiple Myeloma (Kahler's Disease) - Pipeline by Hutchison MediPharma Limited, H1 2015 146
Multiple Myeloma (Kahler's Disease) - Pipeline by Immune System Therapeutics Ltd., H1 2015 147
Multiple Myeloma (Kahler's Disease) - Pipeline by ImmunoCellular Therapeutics, Ltd., H1 2015 148
Multiple Myeloma (Kahler's Disease) - Pipeline by Immunocore Limited, H1 2015 149
Multiple Myeloma (Kahler's Disease) - Pipeline by Immunomedics, Inc., H1 2015 150
Multiple Myeloma (Kahler's Disease) - Pipeline by Immunomic Therapeutics, Inc., H1 2015 151
Multiple Myeloma (Kahler's Disease) - Pipeline by Incyte Corporation, H1 2015 152
Multiple Myeloma (Kahler's Disease) - Pipeline by Innate Pharma SA, H1 2015 153
Multiple Myeloma (Kahler's Disease) - Pipeline by Jasco Pharmaceuticals, LLC., H1 2015 154
Multiple Myeloma (Kahler's Disease) - Pipeline by Johnson and Johnson, H1 2015 155
Multiple Myeloma (Kahler's Disease) - Pipeline by JW Pharmaceutical Corporation, H1 2015 156
Multiple Myeloma (Kahler's Disease) - Pipeline by KaloBios Pharmaceuticals, Inc., H1 2015 157
Multiple Myeloma (Kahler's Disease) - Pipeline by Kancera AB, H1 2015 158
Multiple Myeloma (Kahler's Disease) - Pipeline by Karyopharm Therapeutics, Inc., H1 2015 159
Multiple Myeloma (Kahler's Disease) - Pipeline by MandalMed, Inc., H1 2015 160
Multiple Myeloma (Kahler's Disease) - Pipeline by MedImmune, LLC, H1 2015 161
Multiple Myeloma (Kahler's Disease) - Pipeline by Merck and Co., Inc., H1 2015 162
Multiple Myeloma (Kahler's Disease) - Pipeline by Merus B.V., H1 2015 163
Multiple Myeloma (Kahler's Disease) - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 164
Multiple Myeloma (Kahler's Disease) - Pipeline by Mirna Therapeutics, Inc., H1 2015 165
Multiple Myeloma (Kahler's Disease) - Pipeline by Modulation Therapeutics, Inc., H1 2015 166
Multiple Myeloma (Kahler's Disease) - Pipeline by Molecular Templates Inc., H1 2015 167
Multiple Myeloma (Kahler's Disease) - Pipeline by MolMed S.p.A., H1 2015 168
Multiple Myeloma (Kahler's Disease) - Pipeline by MorphoSys AG, H1 2015 169
Multiple Myeloma (Kahler's Disease) - Pipeline by Nippon Kayaku Co., Ltd., H1 2015 170
Multiple Myeloma (Kahler's Disease) - Pipeline by Nordic Nanovector ASA, H1 2015 171
Multiple Myeloma (Kahler's Disease) - Pipeline by Novartis AG, H1 2015 172
Multiple Myeloma (Kahler's Disease) - Pipeline by Noxxon Pharma AG, H1 2015 173
Multiple Myeloma (Kahler's Disease) - Pipeline by Oncolytics Biotech Inc., H1 2015 174
Multiple Myeloma (Kahler's Disease) - Pipeline by Onconova Therapeutics, Inc., H1 2015 175
Multiple Myeloma (Kahler's Disease) - Pipeline by OncoPep Inc., H1 2015 176
Multiple Myeloma (Kahler's Disease) - Pipeline by Oncopeptides AB, H1 2015 177
Multiple Myeloma (Kahler's Disease) - Pipeline by Onyx Pharmaceuticals, Inc., H1 2015 178
Multiple Myeloma (Kahler's Disease) - Pipeline by Otsuka Holdings Co., Ltd., H1 2015 179
Multiple Myeloma (Kahler's Disease) - Pipeline by Panacela Labs, Inc., H1 2015 180
Multiple Myeloma (Kahler's Disease) - Pipeline by Patrys Limited, H1 2015 181
Multiple Myeloma (Kahler's Disease) - Pipeline by Pfizer Inc., H1 2015 182
Multiple Myeloma (Kahler's Disease) - Pipeline by Pharma Mar, S.A., H1 2015 183
Multiple Myeloma (Kahler's Disease) - Pipeline by Pharmacyclics, Inc., H1 2015 184
Multiple Myeloma (Kahler's Disease) - Pipeline by Polyphor Ltd., H1 2015 185
Multiple Myeloma (Kahler's Disease) - Pipeline by Pono Pharma, H1 2015 186
Multiple Myeloma (Kahler's Disease) - Pipeline by Prescient Therapeutics Ltd, H1 2015 187
Multiple Myeloma (Kahler's Disease) - Pipeline by Priaxon AG, H1 2015 188
Multiple Myeloma (Kahler's Disease) - Pipeline by Progenra, Inc., H1 2015 189
Multiple Myeloma (Kahler's Disease) - Pipeline by Prolexys Pharmaceuticals, Inc., H1 2015 190
Multiple Myeloma (Kahler's Disease) - Pipeline by Quest PharmaTech Inc., H1 2015 191
Multiple Myeloma (Kahler's Disease) - Pipeline by Rhizen Pharmaceuticals SA, H1 2015 192
Multiple Myeloma (Kahler's Disease) - Pipeline by Sanofi, H1 2015 193
Multiple Myeloma (Kahler's Disease) - Pipeline by Selexys Pharmaceuticals Corporation, H1 2015 194
Multiple Myeloma (Kahler's Disease) - Pipeline by Senhwa Biosciences, Inc., H1 2015 195
Multiple Myeloma (Kahler's Disease) - Pipeline by Sigma-Tau S.p.A., H1 2015 196
Multiple Myeloma (Kahler's Disease) - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2015 197
Multiple Myeloma (Kahler's Disease) - Pipeline by Stemline Therapeutics, Inc., H1 2015 198
Multiple Myeloma (Kahler's Disease) - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 199
Multiple Myeloma (Kahler's Disease) - Pipeline by Synta Pharmaceuticals Corp., H1 2015 200
Multiple Myeloma (Kahler's Disease) - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2015 201
Multiple Myeloma (Kahler's Disease) - Pipeline by Targazyme, Inc., H1 2015 202
Multiple Myeloma (Kahler's Disease) - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 203
Multiple Myeloma (Kahler's Disease) - Pipeline by TG Therapeutics, Inc., H1 2015 204
Multiple Myeloma (Kahler's Disease) - Pipeline by Theravectys S.A., H1 2015 205
Multiple Myeloma (Kahler's Disease) - Pipeline by Threshold Pharmaceuticals, Inc., H1 2015 206
Multiple Myeloma (Kahler's Disease) - Pipeline by Tragara Pharmaceuticals, Inc., H1 2015 207
Multiple Myeloma (Kahler's Disease) - Pipeline by Transgene Biotek Limited, H1 2015 208
Multiple Myeloma (Kahler's Disease) - Pipeline by Vaccibody AS, H1 2015 209
Multiple Myeloma (Kahler's Disease) - Pipeline by Vaccinex, Inc., H1 2015 210
Multiple Myeloma (Kahler's Disease) - Pipeline by Vaxil Bio Therapeutics Ltd., H1 2015 211
Multiple Myeloma (Kahler's Disease) - Pipeline by Verastem, Inc., H1 2015 212
Multiple Myeloma (Kahler's Disease) - Pipeline by Vivolux AB, H1 2015 213
Multiple Myeloma (Kahler's Disease) - Pipeline by XBiotech USA, Inc., H1 2015 214
Multiple Myeloma (Kahler's Disease) - Pipeline by Xencor, Inc., H1 2015 215
Multiple Myeloma (Kahler's Disease) - Pipeline by XTL Biopharmaceuticals Ltd., H1 2015 216
Multiple Myeloma (Kahler's Disease) - Pipeline by Zyngenia, Inc., H1 2015 217
Assessment by Monotherapy Products, H1 2015 218
Assessment by Combination Products, H1 2015 219
Number of Products by Stage and Target, H1 2015 221
Number of Products by Stage and Mechanism of Action, H1 2015 233
Number of Products by Stage and Route of Administration, H1 2015 244
Number of Products by Stage and Molecule Type, H1 2015 246
Multiple Myeloma (Kahler's Disease) Therapeutics - Recent Pipeline Updates, H1 2015 693
Multiple Myeloma (Kahler's Disease) - Dormant Projects, H1 2015 952
Multiple Myeloma (Kahler's Disease) - Dormant Projects (Contd..1), H1 2015 953
Multiple Myeloma (Kahler's Disease) - Dormant Projects (Contd..2), H1 2015 954
Multiple Myeloma (Kahler's Disease) - Dormant Projects (Contd..3), H1 2015 955
Multiple Myeloma (Kahler's Disease) - Dormant Projects (Contd..4), H1 2015 956
Multiple Myeloma (Kahler's Disease) - Dormant Projects (Contd..5), H1 2015 957
Multiple Myeloma (Kahler's Disease) - Dormant Projects (Contd..6), H1 2015 958
Multiple Myeloma (Kahler's Disease) - Dormant Projects (Contd..7), H1 2015 959
Multiple Myeloma (Kahler's Disease) - Dormant Projects (Contd..8), H1 2015 960
Multiple Myeloma (Kahler's Disease) - Dormant Projects (Contd..9), H1 2015 961
Multiple Myeloma (Kahler's Disease) - Dormant Projects (Contd..10), H1 2015 962
Multiple Myeloma (Kahler's Disease) - Dormant Projects (Contd..11), H1 2015 963
Multiple Myeloma (Kahler's Disease) - Dormant Projects (Contd..12), H1 2015 964
Multiple Myeloma (Kahler's Disease) - Dormant Projects (Contd..13), H1 2015 965
Multiple Myeloma (Kahler's Disease) - Dormant Projects (Contd..14), H1 2015 966
Multiple Myeloma (Kahler's Disease) - Dormant Projects (Contd..15), H1 2015 967
Multiple Myeloma (Kahler's Disease) - Dormant Projects (Contd..16), H1 2015 968
Multiple Myeloma (Kahler's Disease) - Discontinued Products, H1 2015 969
Multiple Myeloma (Kahler's Disease) - Discontinued Products (Contd..1), H1 2015 970
Multiple Myeloma (Kahler's Disease) - Discontinued Products (Contd..2), H1 2015 971
Multiple Myeloma (Kahler's Disease) - Discontinued Products (Contd..3), H1 2015 972
Multiple Myeloma (Kahler's Disease) - Discontinued Products (Contd..4), H1 2015 973

List of Figures
Number of Products under Development for Multiple Myeloma (Kahler's Disease), H1 2015 39
Number of Products under Development for Multiple Myeloma (Kahler's Disease) - Comparative Analysis, H1 2015 40
Number of Products under Development by Companies, H1 2015 41
Number of Products under Investigation by Universities/Institutes, H1 2015 54
Comparative Analysis by Late Stage Development, H1 2015 58
Comparative Analysis by Clinical Stage Development, H1 2015 59
Comparative Analysis by Early Stage Products, H1 2015 60
Assessment by Monotherapy Products, H1 2015 218
Assessment by Combination Products, H1 2015 219
Number of Products by Top 10 Targets, H1 2015 220
Number of Products by Stage and Top 10 Targets, H1 2015 220
Number of Products by Top 10 Mechanism of Actions, H1 2015 232
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 232
Number of Products by Top 10 Routes of Administration, H1 2015 243
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 243
Number of Products by Top 10 Molecule Types, H1 2015 245
Number of Products by Stage and Top 10 Molecule Types, H1 2015 245

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

EpiCast Report: Multiple Myeloma - Epidemiology Forecast to 2023

EpiCast Report: Multiple Myeloma - Epidemiology Forecast to 2023

  • $ 3 995
  • Company report
  • July 2015
  • by Global Data

EpiCast Report: Multiple Myeloma - Epidemiology Forecast to 2023 Summary Multiple myeloma is a hematologic cancer of the white blood cell; more specifically, multiple myeloma is a cancer of the plasma ...

Liver Cancer - Pipeline Review, H1 2015

Liver Cancer - Pipeline Review, H1 2015

  • $ 2 500
  • Company report
  • June 2015
  • by Global Markets Direct

Liver Cancer - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Liver Cancer - Pipeline Review, H1 2015’, provides an overview of the Liver Cancer’s therapeutic pipeline. This report ...

Colorectal Cancer - Pipeline Review, H1 2015

Colorectal Cancer - Pipeline Review, H1 2015

  • $ 2 500
  • Company report
  • June 2015
  • by Global Markets Direct

Colorectal Cancer - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Colorectal Cancer - Pipeline Review, H1 2015’, provides an overview of the Colorectal Cancer’s therapeutic pipeline. ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.